Cargando…
Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma
PURPOSE: The signal transducer and activator of transcription 3 (STAT3) signaling pathway might be a promising therapeutic target for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: This study was a multicenter, open-label, non-comparative, dose escalating phase I study of OPB-111077, an oral...
Autores principales: | Yoo, Changhoon, Kang, Jihoon, Lim, Ho Yeong, Kim, Jee Hyun, Lee, Myung-Ah, Lee, Kyung-Hun, Kim, Tae-You, Ryoo, Baek-Yeol |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473286/ https://www.ncbi.nlm.nih.gov/pubmed/29898591 http://dx.doi.org/10.4143/crt.2018.226 |
Ejemplares similares
-
A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
por: Tolcher, Anthony, et al.
Publicado: (2018) -
Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
por: Oh, Do-Youn, et al.
Publicado: (2015) -
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
por: Hayakawa, F, et al.
Publicado: (2013) -
STAT3 Inhibitor OPB-51602 Is Cytotoxic to Tumor Cells Through Inhibition of Complex I and ROS Induction
por: Brambilla, Lara, et al.
Publicado: (2020) -
Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion
por: Yoo, Changhoon, et al.
Publicado: (2021)